BACKGROUND: Patients with acute ischemic stroke (AIS) commonly have elevated blood pressure (BP). Guidelines have recommended against treatment with intravenous tissue plasminogen activator (tPA) when aggressive measures such as continuous infusion with nicardipine hydrochloride are required to maintain BP lower than 185/110 mm Hg. We evaluated the effect of elevated BP and its management on clinical outcomes after tPA therapy in AIS. OBJECTIVES: To evaluate safety and outcome in patients with AIS who require treatment to lower BP before tPA therapy and to compare safety and outcome in patients who received aggressive treatment with nicardipine with those who received labetalol hydrochloride before tPA. DESIGN: Retrospective review of medical records for all patients who received intravenous tPA within 3 hours of AIS onset. SETTING: Emergency department. Patients One hundred seventy-eight patients with AIS treated with tPA. MAIN OUTCOME MEASURES: Occurrence of symptomatic intracerebral hemorrhage and neurologic deterioration. RESULTS: Fifty patients required BP lowering before tPA therapy. Twenty-four of these patients (48%) received nicardipine either after labetalol or as first-line therapy. Patients requiring antihypertensive agents had higher baseline blood glucose concentrations, incidence of hypertension, and National Institutes of Health Stroke Scale scores. The rate of adverse events and of modified Rankin score at discharge were not significantly different in patients without BP-lowering treatment compared with patients given either labetalol or nicardipine before intravenous tPA therapy. CONCLUSIONS: Blood pressure lowering before intravenous tPA therapy, even using aggressive measures, may not be associated with a higher rate of hemorrhage or poor outcome. Data suggest that patients with AIS requiring aggressive treatment to lower BP should not be excluded from receiving tPA therapy. A prospective study is needed to support these conclusions.
BACKGROUND:Patients with acute ischemic stroke (AIS) commonly have elevated blood pressure (BP). Guidelines have recommended against treatment with intravenous tissue plasminogen activator (tPA) when aggressive measures such as continuous infusion with nicardipine hydrochloride are required to maintain BP lower than 185/110 mm Hg. We evaluated the effect of elevated BP and its management on clinical outcomes after tPA therapy in AIS. OBJECTIVES: To evaluate safety and outcome in patients with AIS who require treatment to lower BP before tPA therapy and to compare safety and outcome in patients who received aggressive treatment with nicardipine with those who received labetalol hydrochloride before tPA. DESIGN: Retrospective review of medical records for all patients who received intravenous tPA within 3 hours of AIS onset. SETTING: Emergency department. Patients One hundred seventy-eight patients with AIS treated with tPA. MAIN OUTCOME MEASURES: Occurrence of symptomatic intracerebral hemorrhage and neurologic deterioration. RESULTS: Fifty patients required BP lowering before tPA therapy. Twenty-four of these patients (48%) received nicardipine either after labetalol or as first-line therapy. Patients requiring antihypertensive agents had higher baseline blood glucose concentrations, incidence of hypertension, and National Institutes of Health Stroke Scale scores. The rate of adverse events and of modified Rankin score at discharge were not significantly different in patients without BP-lowering treatment compared with patients given either labetalol or nicardipine before intravenous tPA therapy. CONCLUSIONS: Blood pressure lowering before intravenous tPA therapy, even using aggressive measures, may not be associated with a higher rate of hemorrhage or poor outcome. Data suggest that patients with AIS requiring aggressive treatment to lower BP should not be excluded from receiving tPA therapy. A prospective study is needed to support these conclusions.
Authors: Harold P Adams; Robert J Adams; Thomas Brott; Gregory J del Zoppo; Anthony Furlan; Larry B Goldstein; Robert L Grubb; Randall Higashida; Chelsea Kidwell; Thomas G Kwiatkowski; John R Marler; George J Hademenos Journal: Stroke Date: 2003-04 Impact factor: 7.914
Authors: P E Aylward; R G Wilcox; J H Horgan; H D White; C B Granger; R M Califf; E J Topol Journal: Ann Intern Med Date: 1996-12-01 Impact factor: 25.391
Authors: David Tanne; Scott E Kasner; Andrew M Demchuk; Nira Koren-Morag; Sandra Hanson; Martin Grond; Steven R Levine Journal: Circulation Date: 2002-04-09 Impact factor: 29.690
Authors: T Brott; M Lu; R Kothari; S C Fagan; M Frankel; J C Grotta; J Broderick; T Kwiatkowski; C Lewandowski; E C Haley; J R Marler; B C Tilley Journal: Stroke Date: 1998-08 Impact factor: 7.914
Authors: Dawn Kleindorfer; Brett Kissela; Alex Schneider; Daniel Woo; Jane Khoury; Rosemary Miller; Kathleen Alwell; James Gebel; Jerzy Szaflarski; Arthur Pancioli; Edward Jauch; Charles Moomaw; Rakesh Shukla; Joseph P Broderick Journal: Stroke Date: 2004-01-22 Impact factor: 7.914
Authors: José Castillo; Rogelio Leira; María M García; Joaquín Serena; Miguel Blanco; Antoni Dávalos Journal: Stroke Date: 2004-01-15 Impact factor: 7.914
Authors: Richard Leigh; Osama O Zaidat; Muhammad F Suri; Gwendolyn Lynch; Sophia Sundararajan; Jeffrey L Sunshine; Robert Tarr; Warren Selman; Dennis M D Landis; Jose I Suarez Journal: Stroke Date: 2004-06-03 Impact factor: 7.914
Authors: Michael J Lyerly; Karen C Albright; Amelia K Boehme; Reza Bavarsad Shahripour; James T Houston; Pawan V Rawal; Niren Kapoor; Muhammad Alvi; April Sisson; Anne W Alexandrov; Andrei V Alexandrov Journal: J Stroke Cerebrovasc Dis Date: 2013-08-15 Impact factor: 2.136
Authors: Lesli E Skolarus; Phillip A Scott; James F Burke; Eric E Adelman; Shirley M Frederiksen; Allison M Kade; Jack D Kalbfleisch; Andria L Ford; William J Meurer Journal: Stroke Date: 2012-10-02 Impact factor: 7.914
Authors: Michael J Lyerly; Karen C Albright; Amelia K Boehme; Reza Bavarsad Shahripour; James T Houston; Pawan V Rawal; Niren Kapoor; Muhammad Alvi; April Sisson; Anne W Alexandrov; Andrei V Alexandrov Journal: J Neurol Disord Stroke Date: 2013-09-13
Authors: T P Zonneveld; A Algra; D W J Dippel; L J Kappelle; R J van Oostenbrugge; Y B W E M Roos; M J Wermer; H B van der Worp; P J Nederkoorn; N D Kruyt Journal: BMC Neurol Date: 2015-11-23 Impact factor: 2.474